Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge in $591 Million Deal with LogicBio for Gene Therapies

publication date: Apr 27, 2021

CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus (AAV) sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge also will have an option on sL65 for two additional indications and an option on LogicBio's lead drug, LB-001, in China. CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. If the other two options are exercised and all milestones are achieved, CANbridge would make $581 million in payments. Based in Boston, LogicBio develops gene therapies for rare diseases in children. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital